Reality from the Vision - Pharma Supply Chain Performance
James J. Curry
The End-to-End Supply Chain Track at the 2018 ISPE Annual Meeting & Expo
Excellence in pharmaceutical supply chain performance is a key to creating “Reality from the Vision”. At the 2018 ISPE Annual Meeting & Expo, we will hear from two keynotes that will focus on the importance of innovation and management of our manufacturing and complex supply chains.
The End-to-End Supply Chain Track is going to help you create the “Reality” in “Reality from the Vision”. We have some exciting complementary sessions that will address many dimensions of the supply chain including:
Impacts of various types of change
Importance of our people across the supply chain
The End-to-End Supply Chain Track includes sessions on the following topics:
Building a Framework for Site Master Plans
Using Simulation for Capacity Planning Across the Supply Chain
Lessons Learned from Hurricane Maria in Puerto Rico
Techniques to Improve Human Performance in the Supply Chain
Sustainable Serialization Solutions
How to Achieve Container Closure Integrity in Packaging
Supply Chain Innovations for Individual Patient CAR-T Therapies
Industry 4.0: What’s Next - Solutions to Critical Supply Chain Issues
Our session leaders and speakers are putting together a mix of practical experience case studies and forward looking innovative ideas for you to take away valuable knowledge to your company.
I look forward to meeting you in Philadelphia this November at the 2018 ISPE Annual Meeting & Expo – come and join us as we explore ways to achieve excellence.
A record-setting 640 attendees gathered in Rome in March for the 2018 ISPE Europe Annual Conference. More than 70 sessions offered the latest thinking on topics including facilities of the future, digitization, mass serialization, and the need for data...
MTF is a supplier of Allograft – bone and dermal tissue. The purpose of this isolator project involves the production of Demineralized Bone Matrix (DBX) putty. DBX putty is processed human bone that has been demineralized and combined with sodium...
Gilead Science’s 28 August purchase of Kite Pharma, Inc., one of the companies developing CAR T-cells, a therapy that harnesses the body’s own immune system to recognize and attack malignant cells, paid off in spades last week. On Wednesday, 18 October,...